Intec Pharma (NTEC) Receives European Patent Related to Carbidopa/Levodopa Accordion Pill

September 6, 2016 7:33 AM EDT
Get Alerts NTEC Hot Sheet
Trade NTEC Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Intec Pharma Ltd. (Nasdaq: NTEC) announces that the European Patent Office has granted a European patent for an Accordion Pill containing certain drugs, including the combination Carbidopa and Levodopa. The patent, granted under No. 2276473, is titled “Gastroretentive Drug Delivery for Carbidopa / Levodopa” and is currently scheduled to remain in force until April 2029. The patent belongs to the company’s IN-7 patent family, which already includes patents granted in the U.S.

“We continue to protect and build upon our solid intellectual property position for our versatile Accordion Pill platform technology,” noted Zeev Weiss, Chief Executive Officer of Intec Pharma. “This European patent is important as it protects key elements of our platform technology, and provides patent protection in Europe for our leading product, the Accordion Pill Carbidopa / Levodopa, currently in a global Phase III clinical trial in advanced Parkinson's disease.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments

Add Your Comment